<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336101">
  <stage>Registered</stage>
  <submitdate>15/10/2010</submitdate>
  <approvaldate>21/10/2010</approvaldate>
  <actrnumber>ACTRN12610000897066</actrnumber>
  <trial_identification>
    <studytitle>The use of non invasive methods to predict drug handling and toxicity of Sunitinib</studytitle>
    <scientifictitle>The utility of genomics and functional imaging to predict Sunitinib pharmacokinetics and pharmacodynamics: The PREDICT SU Study</scientifictitle>
    <utrn />
    <trialacronym>The PREDICT SU Study</trialacronym>
    <secondaryid>PMCC Protocol No 10/56</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic renal cell carcinoma (RCC)</healthcondition>
    <healthcondition>Metastatic Gastrointestinal Stromal Tumuor (GIST)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Standard treatment

Toxicity, response, Pharmacogenomics and Liver Imaging will be observed over 2 cycles of Sunitinib treatment (3 months). 
Total duration of the study 4 years</interventions>
    <comparator>N/A</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Correlate MIBI hepatic functional imaging with the Pharmacokinetics and Toxicity of Sunitinib.
Associations will be assessed to examine the strength and direction of the linear relationship between HFI with PK and toxicity parameters. The Pearson correlation coefficient (for normally distributed variables) or nonparametric Spearman rank correlation (for any non-normally distributed variables) will be calculated with the correlation (r2) and p-value reported. Linear regression models to predict PK parameters from HFI parameters will be fitted to estimate the relationship between pairs of parameters identified as having a significant correlation coefficient. Logistic regression will be used to assess whether HFI parameters can predict presence or absence of toxicity.</outcome>
      <timepoint>Assess response at the 3 months time point then PFS and OS retrospectively</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Correlate the combined Pharmacogenomics of excretory/metabolic and pharmacodynamic enzymes with Sunitinib pharmacokinetics, toxicity and response.
SNP genotypes will be assessed for deviations from Hardy-Weinberg equilibrium. Fisher's exact test or Pearson's chi-square test will be used, as appropriate, to assess the association between SNP genotypes with toxicity and objective response in 2 degree of freedom tests. Linear and logistic regressions will be used to assess the relationship between the number of minor alleles at each SNP with pharmacokinetic, toxicity and response parameters, as appropriate, in 1 degree of freedom tests.</outcome>
      <timepoint>4th year of the project</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Develop and validate a novel non-invasive population dosing model based on MIBI imaging and pharmacogenomic factors, for the safe and effective dosing of Sunitinib.
The genotypic and imaging parameters which showed some evidence of an association with toxicity or response will be tested for inclusion as covariates in logistic regression models for the prediction of toxicity and tumour response. Patient baseline demographics and other measured variables will also be considered. The improvement in model fit, as assessed by chi-squared statistics will determine whether a variable is included in the analysis</outcome>
      <timepoint>4th year of the project</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Cytologically/histologically proven advanced or metastatic renal cell carcinoma (RCC) or gastrointestinal stromal tumour (GIST) after failure of imatinib treatment due to resistance or intolerance with one or more measurable or evaluable lesions, adequate hepatic, bone marrow and renal function,  Eastern Cooperative Oncology Group (ECOG) 2 or less life expectancy greater than 12 weeks, written informed consent for the study and its associated procedures. Patients that are to start Sunitinib therapy for the approved indications.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol or compromises the patient's ability to give informed consent. Conditions that compromise oral absorption, any unresolved toxicity greater than NCI-CTC Grade 2 from previous anti-cancer therapy, co-administration of potent Cytochrome 3A4/5 inducers (phenytoin, carbamazepine, rifampicin, phenobarbitone, St Johns wort) 12 days prior to dosing, co-administration of potent Cytochrome 3A4/5 inhibitors (ketoconazole, erythromycin, clarithromycin, itraconazole, HIV antivirals and grapefruit juice) within 7 days of dosing, uncontrolled hypertension (BP &gt;150/100mmHg despite optimal medical therapy), active bleeding disorders within the last 3 months, NYHA Grade III/IV cardiac problems (e.g. congestive heart failure, or myocardial infarction or active myocardial ischemia within 6 months of study), history of cerebrovascular accident including TIA or pulmonary embolism within 12 months, known diagnosis of human immunodeficiency virus (HIV) infection, active liver disease (e.g., chronic active hepatitis, cirrhosis), major surgery within 21 days prior to commencing study drugs</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/11/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3002</postcode>
    <postcode>3050</postcode>
    <postcode>3084</postcode>
    <postcode>3011</postcode>
    <postcode>3128</postcode>
    <postcode>3199</postcode>
    <postcode>5042</postcode>
    <postcode>5011</postcode>
    <postcode>2065</postcode>
    <postcode>2217</postcode>
    <postcode>2139</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Peter MacCallum Cancer Centre</primarysponsorname>
    <primarysponsoraddress>St Andrews Place, East Melbourne, VIC, 3002</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council of Australia</fundingname>
      <fundingaddress>Level 1
16 Marcus Clarke Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc Prof. Michael Jefford</othercollaboratorname>
      <othercollaboratoraddress>Division of Haematology and Medical Oncology
Peter MacCallum Cancer Centre
St Andrew's Place, East Melbourne, VIC, 3002</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Prof J Zalcberg</othercollaboratorname>
      <othercollaboratoraddress>Division of Haematology and Medical Oncology
Peter MacCallum Cancer Centre
St Andrew's Place, East Melbourne, VIC, 3002</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr C Cullinane</othercollaboratorname>
      <othercollaboratoraddress>Translational Research Laboratory
Peter MacCallum Cancer Centre
St Andrew's Place, East Melbourne,  VIC, 3002</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc Prof Ian Campbell</othercollaboratorname>
      <othercollaboratoraddress>Cancer Genetics
Peter MacCallum Cancer Centre 
St Andrew's Place, East Melbourne,  VIC, 3002</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc Prof. N Tebbutt</othercollaboratorname>
      <othercollaboratoraddress>Dept of Medical Oncology
Austin Hospital
Studley Road, Heidelberg Heights, VIC, 3084</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Prof A Scott</othercollaboratorname>
      <othercollaboratoraddress>Dept of Nuclear Medicine and Ludwig Institute
Studley Road, Heidelberg Heights, VIC, 3084</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc Prof L Lipton</othercollaboratorname>
      <othercollaboratoraddress>Medical Oncology and Clinical Haematology Unit
Western Hospital
Gordon Street, Footscray, VIC, 3011</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr J Desai</othercollaboratorname>
      <othercollaboratoraddress>Dept of Medical Oncology ,
Peter MacCallum Cancer Centre
St Andrew's Place, East Melbourne, VIC, 3002</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Vinod Ganju</othercollaboratorname>
      <othercollaboratoraddress>Department of Medical Oncology
Peninsula Oncology Centre 
24-28 Frankston-Flinders Road, Frankston, VIC, 3199</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Phillip Parente</othercollaboratorname>
      <othercollaboratoraddress>Department of Medical Oncology
Box Hill Hospital
Nelson Road, Box Hill, VIC, 3128</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assco Prof Joe McKendrick</othercollaboratorname>
      <othercollaboratoraddress>Department of Medical Oncology
Box Hill Hospital
Nelson Road, Box Hill, VIC, 3128</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc Prof Sue-Anne McLachlan</othercollaboratorname>
      <othercollaboratoraddress>St Vincent's Hospital
41 Victoria Parade, Fitzroy, VIC, 3065</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Prof S Clarke</othercollaboratorname>
      <othercollaboratoraddress>Dept of Medicine and Medical Oncology
Concord Hospital
Hospital Road, Concord, NSW, 2139</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc Prof L Hovarth</othercollaboratorname>
      <othercollaboratoraddress>Dept of Medical Oncology
Royal Prince Alfred Hospital 
Missenden Road, Camperdown, NSW, 2050</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr W Liauw</othercollaboratorname>
      <othercollaboratoraddress>Dept of Medical Oncology
St Georges Hospital
Gray Street, Kogarah, NSW, 2217</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc Prof M Links</othercollaboratorname>
      <othercollaboratoraddress>Dept of Medical Oncology 
Royal North Shore Hospital
Pacific Highway, St Leonards, NSW, 2065</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr N Pavlakis</othercollaboratorname>
      <othercollaboratoraddress>Dept Medical Oncology
Queen Elizabeth Hospital
Woodville Road, Woodville, SA, 5011</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc Prof T Price</othercollaboratorname>
      <othercollaboratoraddress>Dept Medical Oncology
Flinders Medical Centre
Flinders Drive, Bedford Park, SA, 5042</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr C Karapetis</othercollaboratorname>
      <othercollaboratoraddress>Dept of Medical Oncology
Flinders Medical Centre  
Flinders Drive, Bedford Park, SA, 5042</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Suntinib is a drug with variable PK and toxicity profile that impacts upon its clinical use. This study will be targeted to patients receiving Sunitinib for the treatment of advanced renal cell cancer or GIST. Patients will have functional hepatic imaging and blood taken for pharmacogenomic studies of drug handling and drug target enzyme genes. During treatment patients will be monitored for response and toxicity and have bloods taken for steady state PK. We will then try to correlate PK, toxicity and response with liver imaging and genomic parameters in an attempt to develop doing nomograms.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre Ethics Committee</ethicname>
      <ethicaddress>Level 4, 10 St Andrews Place	                      
East Melbourne, Victoria, 3002</ethicaddress>
      <ethicapprovaldate>3/09/2010</ethicapprovaldate>
      <hrec>PMCC Protocol No: 10/56</hrec>
      <ethicsubmitdate>7/07/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Assoc Prof M Michael</name>
      <address>Division of Haematology and Medical Oncology
Peter MacCallum Cancer Centre
St Andrew's Place, East Melbourne, VIC, 3002</address>
      <phone>+61 3 96561159</phone>
      <fax>+61 3 96561408</fax>
      <email>Michael.Michael@petermac.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Assoc Prof M Michael</name>
      <address>Division of Haematology and Medical Oncology
Peter MacCallum Cancer Centre
St Andrew's Place, East Melbourne, VIC, 3002</address>
      <phone>+61 3 96561159</phone>
      <fax>+61 3 96561408</fax>
      <email>Michael.Michael@petermac.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Assoc Prof M Michael</name>
      <address>Division of Haematology and Medical Oncology
Peter MacCallum Cancer Centre
St Andrew's Place, East Melbourne,  VIC, 3002</address>
      <phone>+61 3 96561159</phone>
      <fax>+61 3 96561408</fax>
      <email>Michael.Michael@petermac.org</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>